<DOC>
	<DOCNO>NCT00099294</DOCNO>
	<brief_summary>The primary objective study evaluate effectiveness safety glufosfamide subject pancreatic cancer previously treat gemcitabine measure overall survival compare best supportive care .</brief_summary>
	<brief_title>Study Efficacy Safety Glufosfamide Compared With Best Supportive Care Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>TH-CR-302 randomize Phase 3 study evaluate efficacy safety glufosfamide plus best supportive care ( BSC ) compare BSC alone second line treatment metastatic pancreatic cancer . BSC include medical surgical intervention pancreatic cancer patient receive palliate cancer exclude treatment systemic therapy intend kill cancer cell . Study Hypothesis : Glufosfamide provide benefit survival patient metastatic pancreatic cancer best supportive care . Comparison : Glufosfamide versus best supportive care .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>At least 18 year age Pancreatic adenocarcinoma proven either histology ( surgical biopsy ) cytology ( CT endoscopicguided ) Metastatic pancreatic cancer Disease progression treatment gemcitabine ( alone combination agent ; regular , radiosensitizing , dos ) advanced/metastatic pancreatic cancer Measurable nonmeasurable disease RECIST criterion ( least one target nontarget lesion ) Recovered reversible toxicity prior therapy Karnofsky performance status â‰¥70 All woman childbearing potential men must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) entry study 6 month last dose Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee More one prior systemic therapy regimen metastatic/locally advance pancreatic cancer ( radiosensitizing dose 5FU gemcitabine time initial radiotherapy count prior systemic therapy regimen ) Hormonal therapy , radiation therapy , biologic therapy , chemotherapy systemic antitumor therapy pancreatic cancer within 14 day prior study start Symptomatic brain metastasis ( baseline CT scan require asymptomatic subject ) Active clinically significant infection require antibiotic Known HIV positive active hepatitis B C Recent ( one year ) history symptom cardiovascular disease ( NYHA Class 2 , 3 , 4 ) , particularly coronary artery disease , arrhythmias conduction defect risk cardiovascular instability , uncontrolled hypertension , clinically significant pericardial effusion , congestive heart failure No active malignancy ( treat nonmelanoma skin cancer treat situ cancer ) within past year Major surgery within 3 week start study treatment , without complete recovery Clinically significant abnormality laboratory test result ( include complete blood count , chemistry panel include electrolyte , urinalysis ) ( Hemoglobin &lt; 9 g/dL ( may receive transfusion erythropoietin maintain ) )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pancreatic Adenocarcinoma</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Glufosfamide</keyword>
</DOC>